Shares of WAVE Life Sciences WVE were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share rose 37.68% over the past year to ($0.86), which missed the estimate of ($0.59).
Revenue of $0 decreased by 100.00% from the same period last year, which missed the estimate of $10,080,000.
Looking Ahead
WAVE Life Sciences hasn't issued any earnings guidance for the time being.
WAVE Life Sciences hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 13, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/spc5r7jo
Recent Stock Performance
52-week high: $19.98
Company's 52-week low was at $4.82
Price action over last quarter: down 35.17%
Company Overview
WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
